search
Back to results

LXR and Oocyte Meiosis Resumption

Primary Purpose

Female Infertility

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
IVF Procedure
Sponsored by
University Hospital, Clermont-Ferrand
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Female Infertility

Eligibility Criteria

18 Years - 36 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • woman aged less 37 years
  • included in a IVF program
  • tubal infertility
  • ovarian stimulation with recombinant FSH
  • induced ovulation by recombinant chorionic gonaotrophin

Exclusion Criteria:

  • dysovulation
  • male infertility
  • Ovarian insuficiency

Sites / Locations

  • CHU Clermont-FerrandRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

women included in a IVF program

Arm Description

Outcomes

Primary Outcome Measures

Expression of RNAs of LXR pathways in granulosa cells surrounding oocyte
The day of the retrieve of granulosa cells, RNA extraction will be performed and the expression of Liver X Receptors genes, their downstream target genes and the enzymes of oxyterols synthesis will be analysed.

Secondary Outcome Measures

Accumulation of lipid in granulosa cells surrounding oocyte
Embryo development of inseminated ovocytes at day 5 after sperm insemination during In Vitro Fertilization process

Full Information

First Posted
January 27, 2017
Last Updated
February 7, 2017
Sponsor
University Hospital, Clermont-Ferrand
search

1. Study Identification

Unique Protocol Identification Number
NCT03045315
Brief Title
LXR and Oocyte Meiosis Resumption
Official Title
Are LXRs Involved in Regulation of Human Oocyte Meiosis Resumption?
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Unknown status
Study Start Date
January 2015 (Actual)
Primary Completion Date
May 2019 (Anticipated)
Study Completion Date
August 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Clermont-Ferrand

4. Oversight

5. Study Description

Brief Summary
Previous studies in animal model showed clearly that lipid homeostasis influence oocyte meiosis resumption. However Liver X Receptors pathway has never been investigated in human ovocyte
Detailed Description
In mice deficient of Liver X Receptor (LXR) genes, the oocytes are unable to resume meiosis. Oxysterols are molecules derived from the cholesterol synthesis pathway. They are ligands of the liver X receptors (LXRs). In human, the LXR signalling pathway has never been investigated in this process. The Investigator propose to analyse in granulosa cells surrounding ovocyte the expression of LXR, their target genes and the enzymes involved in oxysterols synthesis. These granulosa cells are normally retrieved and destroyed 18 hours after sperm insemination of oocytes in a In Vitro Fertilization program. The oocyte meiosis resumption will be considered as positive (Granulosa cell positive, GC+) if a zygote is observed 18 hours after sperm insemination and negative (Granulosa cell negative, GC-) if none zygote appears. Moreover the investigator will analyse the quality of embryo development during 5 days after zygote is formed (normal process of In Vitro Fertilization) . The both populations of granulosa cells (GC+ and GC-) will be compared. The measurements of Liver X Receptor genes and the enzymes involved in oxysterols pathways xill be performed by Reverse Transcription-Polymerase Chain Reaction. The accumulation of lipid in granulosa cells will be measures by oil red staining. By this sudy the investigator will probably find new biological markers of resumption meiosis for women enrolled in In Vitro Fertilization programm. Moreover, data will help to better understand the physiopathology of oocyte meiosis failures.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Female Infertility

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Allocation
N/A
Enrollment
250 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
women included in a IVF program
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
IVF Procedure
Primary Outcome Measure Information:
Title
Expression of RNAs of LXR pathways in granulosa cells surrounding oocyte
Description
The day of the retrieve of granulosa cells, RNA extraction will be performed and the expression of Liver X Receptors genes, their downstream target genes and the enzymes of oxyterols synthesis will be analysed.
Time Frame
at day 1
Secondary Outcome Measure Information:
Title
Accumulation of lipid in granulosa cells surrounding oocyte
Description
Embryo development of inseminated ovocytes at day 5 after sperm insemination during In Vitro Fertilization process
Time Frame
at day 5

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
36 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: woman aged less 37 years included in a IVF program tubal infertility ovarian stimulation with recombinant FSH induced ovulation by recombinant chorionic gonaotrophin Exclusion Criteria: dysovulation male infertility Ovarian insuficiency
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Patrick LACARIN
Phone
04 73 75 11 95
Email
placarin@chu-clermontferrand.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Florence BRUGNON
Organizational Affiliation
University Hospital, Clermont-Ferrand
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Clermont-Ferrand
City
Clermont-Ferrand
ZIP/Postal Code
63003
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patrick LACARIN
Phone
04 73 75 11 95
Email
placarin@chu-clermontferrand.fr
First Name & Middle Initial & Last Name & Degree
Florence BRUGNON

12. IPD Sharing Statement

Learn more about this trial

LXR and Oocyte Meiosis Resumption

We'll reach out to this number within 24 hrs